Xencor Inc. Stock
Price
Target price
€18.50
€18.50
-0.540%
-0.1
-0.540%
€31.38
18.09.24 / Stuttgart Stock Exchange
WKN: A1W96L / Symbol: XNCR / Name: Xencor / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Xencor Inc. Stock
The price for the Xencor Inc. stock decreased slightly today. Compared to yesterday there is a change of -€0.100 (-0.540%).
With 16 Buy predictions and not the single Sell prediction the community is currently very high on Xencor Inc..
With a target price of 31 € there is a hugely positive potential of 67.57% for Xencor Inc. compared to the current price of 18.5 €.
Pros and Cons of Xencor Inc. in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Cons
?
M***** P*******
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Xencor Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Xencor Inc. | -0.540% | 10.119% | 29.371% | -2.632% | -3.141% | -33.810% | -43.094% |
| Ironwood Pharmaceuticals | 1.510% | 6.316% | 3.061% | -51.030% | -60.392% | -60.392% | -54.185% |
| Arrowhead Pharmaceuticals Inc. | 4.280% | -1.604% | -9.199% | -28.986% | -33.576% | -66.102% | -29.548% |
| Novocure Ltd | -2.190% | 1.503% | -2.218% | -12.320% | 11.173% | -85.811% | -77.946% |
Comments
Xencor, Inc. (NASDAQ: XNCR) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $32.00 price target on the stock.
Show more
Ratings data for XNCR provided by MarketBeat
Xencor, Inc. (NASDAQ: XNCR) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $31.00 price target on the stock.
Show more
Ratings data for XNCR provided by MarketBeat
Xencor, Inc. (NASDAQ: XNCR) had its price target lowered by analysts at JPMorgan Chase & Co. from $30.00 to $27.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for XNCR provided by MarketBeat
News
Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Xencor, Inc. (“Xencor”) (Nasdaq: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the
Xencor Announces Pricing of $175 Million Public Offering of Common Stock
Xencor, Inc. (“Xencor”) (Nasdaq: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the
Xencor Announces Proposed Public Offering of Common Stock
Xencor, Inc. (“Xencor”) (Nasdaq: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that it